Publications by authors named "M Gospodarowicz"
Article Synopsis
- - The Lancet Oncology Commission focuses on improving global access to radiotherapy and theranostics, addressing significant disparities between high-income countries and low-income and middle-income countries (LMICs) concerning available treatment resources and trained healthcare professionals.
- - The implementation of hypofractionation techniques in radiotherapy could increase treatment access for millions of patients with prostate and breast cancer, highlighting the need for new technologies in LMICs with existing resources.
- - A global survey revealed variability in the use of radiopharmaceutical therapy, with issues related to supply chains and workforce training impacting access; initiatives like the International Atomic Energy Agency's Rays of Hope program and investment from development banks are encouraged to improve the situation.
Article Synopsis
- The IELSG37 trial investigated whether patients with primary mediastinal B-cell lymphoma (PMBCL) who have a complete metabolic response (CMR) after treatment can safely skip consolidation radiotherapy.
- It was a randomized noninferiority study involving 545 patients, focusing on progression-free survival (PFS) over 30 months, with results showing high PFS rates of 96.2% for observation and 98.5% for radiotherapy.
- The study concluded that avoiding irradiation does not negatively impact survival, highlighting positive outcomes for patients with CMR.
There are no standards in diagnostic and therapeutic approaches to eye care in incomplete eyelid closure due to unresolved facial palsy (FP). Loading of the upper eyelid (UELL) with gold weights (GWs) or platinum chains (PCs) is a highly effective procedure for the correction of lagophthalmos. Despite this, the procedure is used infrequently in our country because of the relatively high price of the implant and the lack of reimbursement.
View Article and Find Full Text PDFImportance: Less than 5% of patients with cancer enroll in a clinical trial, partly due to financial and logistic burdens, especially among underserved populations. The COVID-19 pandemic marked a substantial shift in the adoption of decentralized trial operations by pharmaceutical companies.
Objective: To assess the current global state of adoption of decentralized trial technologies, understand factors that may be driving or preventing adoption, and highlight aspirations and direction for industry to enable more patient-centric trials.